Based on recent reports that peroxisome proliferatoractivated receptor delta (PPARd) activation promotes tumourigenesis, we have investigated the role of this protein in Apc-mediated intestinal tumourigenesis. We demonstrate that the inactivation of Apc in the adult small intestine, while causing the expected nuclear accumulation of b-catenin, does not cause the expected increase in PPARd mRNA or protein but conversely, the levels of PPARd mRNA and protein are lowered. Furthermore, we find that Apc Min PPARd-null mice exhibit an increased predisposition to intestinal tumourigenesis. Our data suggest that PPARd is not directly regulated by bcatenin, and that inhibition of PPARd activity is unlikely to be an appropriate strategy for the chemoprevention or chemotherapy of intestinal malignancies.
Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear hormone receptor superfamily and are ligand-activated transcription factors. PPARd heterodimerizes with retinoic X receptor a to form a transcriptionally competent complex, is expressed in the intestine and is believed to be regulated by the APC/b-catenin/TCF-4 pathway (He et al., 1999) . Previous evidence suggests that PPARd expression is associated with intestinal tumourigenesis, with increased mRNA levels being observed in several colorectal cell (CRC) lines and colon tumours (He et al., 1999; Gupta et al., 2000) . A PPARd-deficient CRC line was defective in establishing tumours when grown as xenografts in nude mice, and the tumours that did arise from this cell line grew slowly (Park et al., 2001) , while the induction of adenomatous polyposis coli (APC) protein in human CRC lines resulted in downregulation of PPARd expression (He et al., 1999) . Furthermore, Gupta et al. (2004) have recently shown that activation of PPARd using a synthetic ligand in mice predisposed to intestinal tumourigenesis (Apc Min mice) resulted in a significant increase in the number and size of intestinal polyps. Similarly, Stephen et al. (2004) have used the same synthetic ligand of PPARd to show that activation of PPARd stimulates proliferation of human breast and prostate cancer cell lines, but interestingly not colon cancer cell lines. Finally, a preliminary study of three mice targeting PPARd in Apc Min mice suggested that, although PPARd is not essential for polyp formation, its removal may tend to result in smaller polyps, although this finding was not proven to be significantly different (Barak et al., 2002) . This data, taken together with the fact that PPARd expression is regulated by nonsteroidal anti-inflammatory drugs (He et al., 1999; Park et al., 2001; Shureiqi et al., 2003) , suggests PPARd is a potential target for intervention in intestinal tumourigenesis. Consequently, we have investigated the role of PPARd in tumourigenesis in two murine model systems. Our results, taken together with other more recent studies, indicate a contrasting role for PPARd in intestinal tumourigenesis and suggest that PPARd is not a good target for intervention in intestinal tumourigenesis.
First, we have used a novel murine system to analyse the immediate effect upon PPARd of loss of Apc in the intestine. Germline mutations of human APC are associated with the syndrome Familial Adenomatous Polyposis, which is characterised by multiple colorectal lesions (Kinzler et al., 1991) . Inactivation of APC is recognised as a key early event in the development of sporadic colorectal cancers. We have developed a novel transgenic line wherein exposure to b-napthoflavone induces expression of Cre recombinase through activation of a CYP1A1 promoter. In conjunction with an Apc allele carrying loxP sites flanking exon 14 (Apc 580S ) (Shibata et al., 1997) , this allows inducible inactivation of Apc. This system delivers near 100% recombination of the target allele in adult murine small intestine . We have used microarray to analyse the expression profiles of adult small intestine tissues 3, 4 and 5 days following the loss of Apc . In contrast to previous results, these data show that PPARd and also PPARa are not upregulated immediately following the loss of Apc, but rather show a reduction in mRNA levels (PPARd shows a 1.8-, 5-and 2.6-fold reduction at days 3, 4 and 5, respectively, while PPARa shows a 1.2-, 3-and 2.2-fold reduction at days 3, 4 and 5, respectively). The failure to observe upregulation of these genes was confirmed by semiquantitative RT-PCR analysis, as expression of c-MYC, a confirmed target of b-catenin, was clearly upregulated in the Apcdeficient samples at days 3, 4 and 5 following Apc recombination, whereas similar upregulation of PPARd and PPARa was not seen (Figure 1a) . However, given the semiquantitative nature of this technique, we have further examined PPARd protein levels by Western blot analysis ( Figure 1b) and immunohistochemistry ( Figure  1c-h) . We show that the reduction in mRNA levels of PPARd from our array correlates with reduced levels of PPARd protein in the Apc-deficient samples (Figure 1b) . Furthermore, we show that nuclear localisation of bcatenin does not correlate with the localisation pattern of PPARd in the normal intestinal structure as would be expected if PPARd was directly regulated by b-catenin Figure 1c , d). We find that PPARd is mainly expressed at the junction region between the top of the crypt to the bottom of the villus ( Figure 1c ), while nuclear localisation of b-catenin is restricted to the cells at the bottom of the crypt (Figure 1d ). PPARd staining is not present in the smallest detectible (single crypt) lesions in both Apcrecombined tissues and Apc Min mice (Figure 1f ), nor in the Apc-deficient tissues ( Figure 1g ). In contrast, nuclear localisation of b-catenin is clearly detectable in these lesions (Kongkanuntn et al., 1999) and in the Apcdeficient tissues (Figure 1h ). Thus, nuclear accumulation of b-catenin, which occurs at day 3 following the loss of Apc , results in lowered levels of PPARd. This, together with the nonoverlapping expression patterns of the two proteins in normal intestine, strongly implies that PPARd is not a direct target of the APC/b-catenin/TCF-4 pathway. Similarly, other reports using a dominant-negative TCF mutant to block TCF/ b-catenin-driven transactivation did not identify any alterations in the levels of PPARd mRNA ( Van de Wetering et al., 2002) . The previous evidence suggesting that PPARd was a target of the APC pathway was from studies using human CRC lines (He et al., 1999) . Given that such cell lines often have multiple aberrations, it is possible that the normal mechanisms controlling PPARd expression in this system are perturbed. Our in vivo study represents a precisely defined genetic system in which to study the expression of genes regulated by the APC/b-catenin/TCF-4 pathway, and shows that PPARd is actually downregulated by activation of this pathway.
It is possible that PPARd expression is upregulated during later stages of tumour progression. However, semiquantitative RT-PCR analysis of large intestinal ademomas collected from Apc Min mice showed that PPARd expression is not upregulated (Figure 1i ). This finding is comparable to data within two recent studies examining patterns of gene expression in the Apc Min mouse. Firstly, one study used Western blot analysis of small intestinal adenomas to show that PPARd protein is maintained, but not upregulated in Apc Min tumours (Orner et al., 2003) , while another study used quantitative RT-PCR to show that the expression levels of both PPARa and PPARd are significantly lower in Apc Min colonic polyps (Chen et al., 2004) . Additionally, a microarray study comparing matched human tumour and normal intestinal tissues found that PPARd mRNA was significantly lower in the tumour samples (Notterman et al., 2001) . Given the number of genes examined within these studies, little or no emphasis was given to the analysis of PPARd expression. However, taken together with our results it is clear that in vivo PPARd expression is not always upregulated in tumourigenesis, and is indeed downregulated in many instances. This is in contrast to previous reports which show that PPARd mRNA expression is increased in several colon cancer model systems including APC haploinsufficiency in CRC lines (He et al., 1999) , azoxymethane-induced colon tumours in rats (Gupta et al., 2000) and human colorectal tumours (Gupta et al., 2000) . The reason for these disparities is uncertain but could reflect differences in the model systems or genetic/chemical-dependent influences. It is still possible that the regulation of PPARd by b-catenin may occur but as a tumour stagespecific phenomenon; however, the results presented from this study using a powerful genetic model of Apc inactivation strongly support the idea that PPARd is not immediately increased in response to Apc inactivation or at the later stage of colonic adenoma.
We next directly addressed the hypothesis that PPARd deficiency would suppress neoplasia by intercrossing PPARd-null mice to Apc Min mice. We produced cohorts of a minimum of 15 animals for each genotype combination (Apc
) and examined survival, adenoma multiplicity and tumour size (Figure 2a-e) . In contrast to a recent report (Harman et al., 2004) , survival of the Apc Min/ þ PPARd À/À was not different as compared to the other two genotypes (Figure 2a) , although the same targeted PPARd allele (Peters et al., 2000) was used in both studies. This discrepancy may arise as a consequence of slight differences in genetic background even though both studies were performed on mice backcrossed to C57BL/6 for six generations. However, consistent with Harman et al. (2004) , we find that loss of PPARd promotes tumourigenesis in Apc Min mice, although the two studies show differences in this increased predisposition.
We found that the number of adenomas in the small intestine did not differ between the cohorts (Figure 2b ), but that there was a significant increase (Po0.001 MannWhitney test) in the size of tumours in the small intestine, independent of sex, in the Apc Min/ þ PPARd À/À cohort (Figure 2c . Furthermore, in the large intestine, we found tht there was a significant increase (Po0.05 Mann-Whitney test) in the number of polyps in the Apc Min/ þ PPARd À/À cohort, which is specific to females (Figure 2d ). In contrasts, Harman et al. (2004) found increased numbers of polyps in both males and females. The reasons for the differences between the two studies remain unclear but probably arise from either subtle differences in the genetic background of the mice, dietary or environmental influences. One possibility is that they reflect differences in the normal profile of PPARd expression along the length of the gastrointestinal tract. However, critically, both studies show a trend to increased tumourigenesis in the Apc Min/ þ PPARd À/À cohorts. Interestingly, this is more pronounced in the female mice, and gender-specific . The details for the primers used are given in supplementary methods. Note, we do not see the expected upregulation of PPARd expression in the ApcFlox samples, but did detect upregulation of cMYC at the three time points analysed. In order to ensure that the RT-PCR reactions did not reach saturation, the minimum number of cycles to produce a visible product was used. RT-PCR procedures are described in the supplementary methods. For each RT-PCR, the intensity of the bands on an ethidium bromide-stained agarose gel was quantified using Quantity-one software (Biorad) Min/ þ mice cohorts. Mice were generated from sixth generation C57BL/6 backcrossed mice. All experiments were performed according to UK Home Office regulations. Littermates for each of the required genotypes were generated, allowed to age and monitored for signs of intestinal tumours. Animals were harvested when they displayed overt symptoms of intestinal disease, including criteria of anaemia (as assessed by pale feet), weight loss and rectal bleeding. The survival curve shows age of each animal at the time of death: Black line,
. Genotyping procedures are described in the supplementary methods. (b-e) Box plots showing the size of adenomas or the number of adenomas per mouse at death. Intestinal preparations were collected from every animal at the time of death as previously described (Sansom et al., 2003) . Following fixation, the number of tumours in the small and large intestine was counted and a size (expressed as width by length) of each tumour was recorded. The box encompasses the first quartile (at bottom) to the third quartile (at top) of the data set, the horizontal boxed line represents the median, while asterisks represent outliers. The number of animals for this study was extended beyond that of the survival cohorts to include all animals in our colony that have died due to intestinal tumour burden: Apc Min/ þ PPARd þ / þ female n ¼ 7, male n ¼ 6; Apc Min/ þ PPARd þ /À female n ¼ 9, male n ¼ 7; Apc Min/ þ PPARd À/À female n ¼ 8, male n ¼ 12. differences in response to PPARd disruption, albeit in other organs, have previously been described (Rosenberger et al., 2002) . In summary, we find no evidence in support of PPARd as a direct target of deregulated Wnt signalling and we find PPARd deficiency actually increases intestinal tumourigenesis in the Apc Min mouse model. We suggest that PPARd deficiency is not equivalent to a lack of PPARd activation and further suggest that PPARd may not represent a good candidate for therapeutic or preventive intervention for intestinal tumourigenesis.
